WO2001064751A2 - High potency recombinant antibodies and method for producing them - Google Patents
High potency recombinant antibodies and method for producing them Download PDFInfo
- Publication number
- WO2001064751A2 WO2001064751A2 PCT/US2001/006815 US0106815W WO0164751A2 WO 2001064751 A2 WO2001064751 A2 WO 2001064751A2 US 0106815 W US0106815 W US 0106815W WO 0164751 A2 WO0164751 A2 WO 0164751A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cdr
- high potency
- antibodies
- amino acid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 123
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 56
- 239000000427 antigen Substances 0.000 claims abstract description 45
- 230000008569 process Effects 0.000 claims abstract description 44
- 108091007433 antigens Proteins 0.000 claims abstract description 43
- 102000036639 antigens Human genes 0.000 claims abstract description 43
- 239000012634 fragment Substances 0.000 claims abstract description 36
- 241000700605 Viruses Species 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 230000000890 antigenic effect Effects 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 208
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 55
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 37
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 12
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 8
- 244000005700 microbiome Species 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 5
- 108700012359 toxins Proteins 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000036515 potency Effects 0.000 description 135
- 210000004027 cell Anatomy 0.000 description 30
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 22
- 238000009739 binding Methods 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 238000003556 assay Methods 0.000 description 14
- 238000010494 dissociation reaction Methods 0.000 description 14
- 230000005593 dissociations Effects 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 230000004071 biological effect Effects 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 241000144290 Sigmodon hispidus Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004896 polypeptide structure Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01914657A EP1259547B1 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
| ES01914657T ES2390761T3 (es) | 2000-03-01 | 2001-03-01 | Anticuerpos recombinantes de alta potencia y método para producción de los mismos |
| AU2001240020A AU2001240020B9 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
| JP2001564244A JP2003525061A (ja) | 2000-03-01 | 2001-03-01 | 高効力組換え抗体およびその産生法 |
| DK01914657.0T DK1259547T3 (da) | 2000-03-01 | 2001-03-01 | Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf |
| AU4002001A AU4002001A (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
| CA002401652A CA2401652A1 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
| AU2006203134A AU2006203134B2 (en) | 2000-01-27 | 2006-07-21 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| AU2007202040A AU2007202040B2 (en) | 2000-03-01 | 2007-05-08 | High potency recombinant antibodies and method for producing them |
| AU2010202006A AU2010202006B2 (en) | 2000-01-27 | 2010-05-18 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| AU2010219289A AU2010219289B2 (en) | 2000-03-01 | 2010-09-03 | High potency recombinant antibodies and method for producing them |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18625200P | 2000-03-01 | 2000-03-01 | |
| US60/186,252 | 2000-03-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001064751A2 true WO2001064751A2 (en) | 2001-09-07 |
| WO2001064751A3 WO2001064751A3 (en) | 2001-12-20 |
Family
ID=22684221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/006815 WO2001064751A2 (en) | 2000-01-27 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
Country Status (10)
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1345625A2 (en) * | 2000-11-28 | 2003-09-24 | Mediummune, Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| WO2003105894A1 (en) * | 2002-06-14 | 2003-12-24 | Medimmune, Inc. | Stabilized liquid anti-rsv antibody formulations |
| WO2004067568A3 (en) * | 2003-01-24 | 2004-10-07 | Applied Molecular Evolution | Human il-1 beta antagonists |
| EP1501870A2 (en) * | 2001-11-02 | 2005-02-02 | Centocor Inc. | Rsv proteins, antibodies, compositions, methods and uses |
| US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7364742B2 (en) | 2003-06-06 | 2008-04-29 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| US10035843B2 (en) | 2009-10-06 | 2018-07-31 | Medimmune Limited | RSV-specific binding molecule |
| EP3387019A4 (en) * | 2015-12-09 | 2019-04-17 | The California Institute for Biomedical Research | RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
| DK1259547T3 (da) | 2000-03-01 | 2012-10-15 | Medimmune Inc | Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7714113B2 (en) * | 2002-02-13 | 2010-05-11 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| US20040091486A1 (en) * | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| CA2485373A1 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| CA2494485A1 (en) * | 2002-07-25 | 2004-02-05 | Medimmune, Inc. | Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| WO2004092343A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| WO2005079479A2 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| AU2004324464A1 (en) * | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU2005302453A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Llc | Methods of preventing and treating RSV infections and related conditions |
| WO2007101441A1 (en) * | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| WO2008070042A2 (en) * | 2006-12-04 | 2008-06-12 | Medimmune, Inc. | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| EP2134747A2 (en) * | 2007-03-06 | 2009-12-23 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
| NZ599338A (en) | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
| EP2501722A4 (en) * | 2009-11-19 | 2013-05-01 | Univ Singapore | METHOD FOR PRODUCING MONOCLONAL ANTIBODIES LIKE T-LYMPHOCYTE RECEPTORS AND USES THEREOF |
| EP2704743B1 (en) | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| AR086515A1 (es) | 2011-05-20 | 2013-12-18 | Alderbio Holdings Llc | Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea |
| SI3495392T1 (sl) | 2011-05-20 | 2021-11-30 | H. Lundbeck A/S | Sestavki proti CGRP in uporaba le-teh |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| EP3974447A3 (en) | 2016-10-21 | 2022-09-07 | Adimab, LLC | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| JP7265984B2 (ja) | 2016-10-21 | 2023-04-27 | アディマブ， エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
| WO2018075961A1 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| AU2020206241A1 (en) | 2019-01-08 | 2021-08-26 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043272B1 (en) | 1980-07-01 | 1984-06-13 | National Research Development Corporation | Production of viral antigens |
| WO1982003089A1 (en) | 1981-03-06 | 1982-09-16 | Lennox Edwin Samuel | Monoclonal antibody |
| DE3378250D1 (en) * | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US5340926A (en) | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US5332805A (en) | 1984-02-03 | 1994-07-26 | Celltech Limited | Process for the recovery of recombinantly produced chymosin from insoluble aggregate |
| US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4717766A (en) | 1986-01-27 | 1988-01-05 | Miles Laboratories, Inc. | Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin |
| US4659563A (en) | 1986-01-27 | 1987-04-21 | Miles Laboratories, Inc. | High titer anti-respiratory syncytial virus intravenous immune globulin |
| US5271927A (en) | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
| US5468606A (en) | 1989-09-18 | 1995-11-21 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US4800078A (en) * | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
| US4880078A (en) * | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| GB8719041D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US4916893A (en) * | 1987-09-02 | 1990-04-17 | Sundstrand Corporation | Multipurpose auxiliary power unit |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
| AU617739B2 (en) | 1987-12-23 | 1991-12-05 | Pharmacia & Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5183657A (en) | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
| JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
| US5137804A (en) | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5354554A (en) | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
| US6093872A (en) | 1989-05-05 | 2000-07-25 | Systemix, Inc. | Extended human hematopoiesis in a heterologous host |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US5518725A (en) | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| WO1991006287A1 (en) * | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5279935A (en) | 1990-03-01 | 1994-01-18 | Becton, Dickinson And Company | Method of immunossay including deactivation of endogenous alkaline phosphatase |
| CA2063408A1 (en) | 1990-05-03 | 1991-11-04 | Susan Mayo | Human lymphoid tissue in an immunocompromised host |
| EP0580737B1 (en) * | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| CA2108259C (en) | 1991-04-22 | 2003-12-09 | George R. Siber | Process of screening plasma samples for effective antibody titers against respiratory viruses |
| ES2181673T3 (es) * | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
| CA2044940A1 (en) | 1991-06-10 | 1992-12-11 | Inder M. Verma | Transdominant negative proto-oncogene |
| US5240694A (en) | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
| US5418136A (en) | 1991-10-01 | 1995-05-23 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
| EP0614530B1 (en) * | 1991-11-15 | 1998-03-04 | Cornell Research Foundation, Inc. | Indirect immunoassay for dioxinlike compounds |
| US20020102257A1 (en) * | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6685942B1 (en) * | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| JP3976333B2 (ja) | 1992-09-16 | 2007-09-19 | ザ スクリップス リサーチ インスティチュート | 呼吸合胞体ウイルスに対するヒト中和性モノクローナル抗体 |
| EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
| US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5424189A (en) | 1993-03-05 | 1995-06-13 | Kansas State University Research Foundation | Bovine respiratory syncytial virus detection and primers |
| EP0724602A4 (en) * | 1993-07-30 | 1998-12-23 | Oravax Inc | MONOCLONAL IgA ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS |
| US5538952A (en) | 1994-05-26 | 1996-07-23 | Abbott Laboratories | Inhibition of infection of mammalian cells by respiratory syncytial virus |
| US5506209A (en) | 1994-05-26 | 1996-04-09 | Abbott Laboratories | Product for inhibition of infection of mammalian cells by respiratory syncytial virus |
| US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| CA2230494A1 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| AU7240096A (en) * | 1995-09-18 | 1997-04-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Neutralizing monoclonal antibodies to respiratory syncytial virus |
| JP2000506165A (ja) * | 1996-03-04 | 2000-05-23 | ザ ペン ステイト リサーチ ファウンデーション | 細胞インターナリゼーションを増強するための物質および方法 |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| FR2758331B1 (fr) | 1997-01-14 | 1999-03-05 | Univ Bourgogne | Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux |
| US6590079B2 (en) * | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| US6117980A (en) * | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7229619B1 (en) * | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
| US20010034062A1 (en) * | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
| DK1259547T3 (da) | 2000-03-01 | 2012-10-15 | Medimmune Inc | Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf |
| AU2001241918A1 (en) * | 2000-03-02 | 2001-09-12 | Med Immune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
| AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| EP1278545A1 (en) * | 2000-05-03 | 2003-01-29 | Medimmune, Inc. | Combination therapy of respiratory diseases using antibodies |
| US7208162B2 (en) * | 2000-05-03 | 2007-04-24 | Medimmune, Inc. | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| ES2244515T3 (es) | 2000-05-03 | 2005-12-16 | Ipv Inheidener Produktions- Und Vertriebsgesellschaft Mbh | Contenedor termico. |
| US20020018780A1 (en) * | 2000-05-25 | 2002-02-14 | Scott Koenig | Epitope-based vaccine for respiratory syncytial virus F-protein |
| WO2002011753A1 (fr) | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Preparations proteiniques a injecter |
| US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| JP4434580B2 (ja) | 2000-11-28 | 2010-03-17 | メディミューン，エルエルシー | 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法 |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| AU2005302453A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Llc | Methods of preventing and treating RSV infections and related conditions |
-
2001
- 2001-03-01 DK DK01914657.0T patent/DK1259547T3/da active
- 2001-03-01 WO PCT/US2001/006815 patent/WO2001064751A2/en active Application Filing
- 2001-03-01 ES ES01914657T patent/ES2390761T3/es not_active Expired - Lifetime
- 2001-03-01 EP EP10010678A patent/EP2341075A1/en not_active Withdrawn
- 2001-03-01 AU AU2001240020A patent/AU2001240020B9/en not_active Ceased
- 2001-03-01 EP EP10010677A patent/EP2341074A1/en not_active Withdrawn
- 2001-03-01 CA CA002401652A patent/CA2401652A1/en not_active Abandoned
- 2001-03-01 US US09/796,848 patent/US7700735B2/en not_active Expired - Fee Related
- 2001-03-01 JP JP2001564244A patent/JP2003525061A/ja active Pending
- 2001-03-01 EP EP01914657A patent/EP1259547B1/en not_active Expired - Lifetime
- 2001-03-01 PT PT01914657T patent/PT1259547E/pt unknown
- 2001-03-01 AU AU4002001A patent/AU4002001A/xx active Pending
-
2007
- 2007-05-08 AU AU2007202040A patent/AU2007202040B2/en not_active Ceased
-
2010
- 2010-02-09 JP JP2010026290A patent/JP2010162025A/ja active Pending
- 2010-02-17 US US12/707,527 patent/US8153133B2/en not_active Expired - Fee Related
- 2010-09-03 AU AU2010219289A patent/AU2010219289B2/en not_active Ceased
-
2012
- 2012-10-05 CY CY20121100934T patent/CY1113298T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5523388A (en) | 1990-08-24 | 1996-06-04 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
Non-Patent Citations (1)
| Title |
|---|
| WU ET AL., PROC. NATL. ACAD. SCI., vol. 95, 1998, pages 6037 - 6042 |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP2412384A1 (en) * | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7553489B2 (en) | 2000-11-28 | 2009-06-30 | Medimmune, Llc | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP2027874A3 (en) * | 2000-11-28 | 2009-06-10 | Medimmune, Inc. | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| EP1345625A2 (en) * | 2000-11-28 | 2003-09-24 | Mediummune, Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| EP2338512A1 (en) * | 2000-11-28 | 2011-06-29 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP1345625A4 (en) * | 2000-11-28 | 2005-06-29 | Mediummune Inc | METHODS OF ADMINISTERING / ASSAYING ANTI-RSV ANTIBODIES FOR PREVENTION AND TREATMENT |
| EP1501870A4 (en) * | 2001-11-02 | 2006-05-03 | Centocor Inc | RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES |
| EP1501870A2 (en) * | 2001-11-02 | 2005-02-02 | Centocor Inc. | Rsv proteins, antibodies, compositions, methods and uses |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| US11180542B2 (en) | 2002-06-14 | 2021-11-23 | Arexis Ab | Stabilized liquid anti-RSV antibody formulations |
| US10604560B2 (en) | 2002-06-14 | 2020-03-31 | Arexis Ab | Stabilized liquid anti-RSV antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US9879067B2 (en) | 2002-06-14 | 2018-01-30 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
| WO2003105894A1 (en) * | 2002-06-14 | 2003-12-24 | Medimmune, Inc. | Stabilized liquid anti-rsv antibody formulations |
| JP2007531509A (ja) * | 2003-01-24 | 2007-11-08 | アプライド モレキュラー エボリューション，インコーポレイテッド | ヒトＩＬ−１βアンタゴニスト |
| US7541033B2 (en) | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
| US7714120B2 (en) | 2003-01-24 | 2010-05-11 | Applied Molecule Evolution, Inc. | Humanized anti-IL-1 beta antibodies |
| JP2010143929A (ja) * | 2003-01-24 | 2010-07-01 | Applied Molecular Evolution Inc | ヒトＩＬ−１βアンタゴニスト |
| WO2004067568A3 (en) * | 2003-01-24 | 2004-10-07 | Applied Molecular Evolution | Human il-1 beta antagonists |
| US7364742B2 (en) | 2003-06-06 | 2008-04-29 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| WO2008147196A3 (en) * | 2007-06-01 | 2009-02-05 | Aimm Therapeutics Bv | Rsv-specific binding molecules and means for producing them |
| US9321831B2 (en) | 2007-06-01 | 2016-04-26 | Medimmune Limited | RSV-specific binding molecules and means for producing them |
| US10730931B2 (en) | 2007-06-01 | 2020-08-04 | Medimmune Limited | RSV-specific binding molecules and means for producing them |
| WO2008147196A2 (en) * | 2007-06-01 | 2008-12-04 | Aimm Therapeutics B.V. | Rsv-specific binding molecules and means for producing them |
| EP2578600A3 (en) * | 2007-06-01 | 2013-07-31 | MedImmune Limited | RSV-specific binding molecules and means for producing them |
| US10059757B2 (en) | 2007-06-01 | 2018-08-28 | Medimmune Limited | RSV-specific binding molecules and means for producing them |
| WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
| US10723786B2 (en) | 2009-10-06 | 2020-07-28 | Medimmune, Limited | RSV-specific binding molecule |
| US10035843B2 (en) | 2009-10-06 | 2018-07-31 | Medimmune Limited | RSV-specific binding molecule |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| EP3387019A4 (en) * | 2015-12-09 | 2019-04-17 | The California Institute for Biomedical Research | RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE |
| US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| EP4011919A3 (en) * | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020098189A1 (en) | 2002-07-25 |
| AU4002001A (en) | 2001-09-12 |
| PT1259547E (pt) | 2012-10-15 |
| CY1113298T1 (el) | 2016-04-13 |
| AU2007202040B2 (en) | 2010-06-10 |
| AU2007202040A1 (en) | 2007-05-24 |
| AU2001240020B9 (en) | 2008-12-04 |
| AU2010219289A1 (en) | 2010-09-30 |
| EP1259547A2 (en) | 2002-11-27 |
| JP2003525061A (ja) | 2003-08-26 |
| WO2001064751A3 (en) | 2001-12-20 |
| AU2001240020B2 (en) | 2007-02-08 |
| US8153133B2 (en) | 2012-04-10 |
| ES2390761T3 (es) | 2012-11-16 |
| EP2341074A1 (en) | 2011-07-06 |
| JP2010162025A (ja) | 2010-07-29 |
| AU2010219289B2 (en) | 2012-05-10 |
| US20100239574A1 (en) | 2010-09-23 |
| EP2341075A1 (en) | 2011-07-06 |
| CA2401652A1 (en) | 2001-09-07 |
| DK1259547T3 (da) | 2012-10-15 |
| US7700735B2 (en) | 2010-04-20 |
| EP1259547B1 (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001240020B2 (en) | High potency recombinant antibodies and method for producing them | |
| AU2001240020A1 (en) | High potency recombinant antibodies and method for producing them | |
| AU785038B2 (en) | Ultra high affinity neutralizing antibodies | |
| US20110027294A1 (en) | Anti-Respiratory Syncytial Virus Antibodies, Antigens and Uses Thereof | |
| JP2010505876A (ja) | ヒトメタニューモウイルスを中和するヒト抗体 | |
| US20230085439A1 (en) | Antibodies that bind human metapneumovirus fusion protein and their use | |
| JP2001510329A (ja) | ヒトモノクローナル抗体 | |
| WO2005056052A1 (en) | Neutralizing human antibodies to anthrax toxin generated by recall technology | |
| AU2012211451A1 (en) | High potency recombinant antibodies and method for producing them | |
| AU2006203015B2 (en) | Ultra high affinity neutralizing antibodies | |
| AU2012213962A1 (en) | Ultra high affinity neutralizing antibodies | |
| CA3210753A1 (en) | Human monoclonal antibodies against pneumococcal antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2001240020 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001914657 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2401652 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564244 Kind code of ref document: A Format of ref document f/p: F |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001914657 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |